Skip to content

FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France

FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France: the FEERIC Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03884413
Acronym
FEERIC
Enrollment
517
Registered
2019-03-21
Start date
2018-03-08
Completion date
2022-03-08
Last updated
2025-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Female

Keywords

breast cancer survivors,, spontaneous fertility rates,, pregnancy,, birth rate,, chemotherapy-induced infertility

Brief summary

FErtility, PrEgnancy, contRaceptIon after breast Cancer in France

Detailed description

Breast cancer is the most common cancer among women. With the increase of the survival rates, a growing attention is paid to the side effects of the treatments, particularly chemotherapy-induced infertility. The FEERIC study will give insights into spontaneous fertility outcomes following breast cancer in comparison with a control cohort and will provide data to help patients counselling towards spontaneous fertility rates following breast cancer. It will also provide data on contraceptive prevalence and unintended pregnancy rates in French breast cancer survivors. Reasons for unmet need for family planning will be deciphered, in order to point out pitfalls (lack of patient's information or orientation/ignorance of contraception methods available/topic insufficiently or not discussed with the physician/ lack of family planning offer etc…); and target the appropriate actions to lead (oncologist and oncology nurses education/ dedicated consultations in breast cancer centers/etc…).

Interventions

OTHERquestionnaires

Longitudinal observational study. Collection of health data using self-administered questionnaires online.

Sponsors

seintinelles network
CollaboratorUNKNOWN
Institut Curie
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 43 Years
Healthy volunteers
Yes

Inclusion criteria

* females aged from 18 to 43 at inclusion * previous diagnosis of breast cancer and time from diagnosis comprised between one and five years or women free from breast cancer or other malignancy (healthy volunteers) .

Exclusion criteria

* hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy * healthy volonteer with history of malignant disease.

Design outcomes

Primary

MeasureTime frameDescription
Spontaneous pregnancies between cases and controls3 yearsOdds ratio between the spontaneous pregnancies between cases and controls, for women with a desire to become pregnant and trying to get pregnant.

Secondary

MeasureTime frameDescription
Time to spontaneous pregnancy3 yearsTime to spontaneous pregnancy after breast cancer diagnosis, for women with a desire to become pregnant and trying to get pregnant.
Contraceptive prevalence3 yearsContraceptive use, defined as the percentage of women reporting use of a contraceptive method.
Rate of women considered with risk of unintended pregnancy3 yearsAn unwanted pregnancy is defined as unwanted at the time of conception. Women are classified as at risk of unwanted pregnancy if they report having had unprotected sex without a desire to become pregnant in the previous four months.
Percentage of live births obtained by medically assisted procreation procedures3 yearsPercentages live births obtained by ARTs procédures, that include in vitro fertilization (IVF) and embryo transfer (ET), intracytoplasmic sperm injection (ICSI) and ovarian stimulation with exogenous gonadotropins.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026